Golgi and Breye partner to develop P2X7 receptor antagonist programme

Golgi Neurosciences has joined forces with Breye Therapeutics for the development of a P2X7 receptor antagonist programme.

Jul 25, 2023 - 20:00

Golgi and Breye partner to develop P2X7 receptor antagonist programme

Golgi Neurosciences has joined forces with Breye Therapeutics for the development of a P2X7 receptor antagonist programme.

Read the original article

Tags:

Previous Article

EMA CHMP provides positive opinion for ViiV’s cabotegravir

Gilead and Cognizant expand deal to expedite digital transformation

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle

US court upholds Avadel’s narcolepsy drug approval amid...

Nov 3, 2024

Opinion: Why the debate over proposed nursing home staff minimums is particularly unproductive

Opinion: Why the debate over proposed nursing home staf...

Feb 5, 2024

Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect

Ahead of Medicare drug price reform, pharma’s drug pric...

Jan 24, 2024